In the entire analyzed group, the risk of progression was not significantly related to age, gender, ALK or ROS1 abnormality testing method (IHC vs. FISH vs. NGS), body weight, smoking status, size and location of tumor, CNS and bone metastases, or treatment toxicities. This evidence concerns the gene ALK and neoplasm.